Charles Riv­er launch­es ‘strate­gic re­view’ along­side ac­tivist in­vestor El­liott

Last week
Outsourcing
Manufacturing

Eu­ro­pean reg­u­la­tors to re­view Val­ne­va shot; Jaz­z's stock dips on sub­par first-quar­ter rev­enue

Last week
News Briefing

Cedars-Sinai part­ners with Re­design Health to build health tech star­tups

Last week
Deals
Health Tech

Theri­va’s on­colyt­ic virus suc­ceeds in pan­cre­at­ic can­cer study, but stock falls

Last week
R&D

What Vinay Prasad means for CBER, vac­cines, drug ap­provals and more

Last week
Pharma
FDA+

CRISPR Ther­a­peu­tic­s' gene edit­ing ther­a­py re­duces bad cho­les­terol and triglyc­erides by as much as 80%

Last week
R&D
Cell/Gene Tx

No­vo Nordisk trims growth fore­cast as GLP-1 com­pounder ban yet to go live

Last week
Pharma

Biotech stocks plunge and in­dus­try fig­ures left to won­der af­ter Prasad's FDA ap­point­ment

Last week
R&D

Marea heads to Phase 2b af­ter up­dat­ed bio­mark­er da­ta show CV drug’s promise

Last week
R&D

Sarep­ta’s stock plum­mets af­ter Prasad ap­point­ment, low Ele­v­idys sales

Last week
Pharma
FDA+

States sue US over plan for re­or­ga­ni­za­tion of fed­er­al health agen­cies

2 weeks ago
Pharma
Law

Ex­clu­sive: SEC ex­pect­ed to drop in­ves­ti­ga­tion of Il­lu­mi­na's $8B Grail deal

2 weeks ago
Deals
Diagnostics

Trump, Con­gress look at match­ing some US drug prices to costs abroad

2 weeks ago
Pharma

Trump, FDA ze­ro in on for­eign fac­to­ries to give do­mes­tic sites an edge  

2 weeks ago
Pharma
FDA+

Eu­rope pledges €500M to at­tract glob­al sci­ence tal­ent

2 weeks ago
People
Pharma

FDA picks con­tro­ver­sial doc­tor Vinay Prasad as CBER di­rec­tor, in about-face from Marks

2 weeks ago
FDA+

Bri­an Arm­strong’s NewLim­it rais­es a $130M Se­ries B, lay­ing out road map for an­ti-ag­ing drugs

2 weeks ago
Financing

Ver­tex paus­es study of mR­NA ther­a­py for cys­tic fi­bro­sis

2 weeks ago
R&D

Lil­ly to pay up to $415M in ALS deal; Ac­tu­ate’s mid-stage pan­cre­at­ic can­cer da­ta

2 weeks ago
News Briefing

Ex­clu­sive: Degra­da­tion start­up rais­es $39M for piv­ot to PRO­TACs and clin­i­cal en­try

2 weeks ago
People
Financing

Aldeyra plots third FDA fil­ing for dry eye dis­ease drug af­ter lat­est Phase 3 da­ta

2 weeks ago
R&D

Sin­ga­pore car­dio gene ther­a­py biotech col­lects $45M as it plots Eu­rope ex­pan­sion

2 weeks ago
Financing
Startups

Ver­tex touts promis­ing first few months of launch for non-opi­oid pain drug Jour­navx

2 weeks ago
Pharma

New opi­oid da­ta may not be gen­er­al­iz­able, FDA ad­comm says

3 weeks ago
Pharma
FDA+
First page Previous page 3456789 Next page Last page
A service from the Financial Times